278 related articles for article (PubMed ID: 19433314)
1. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
Xue A; Xue M; Jackson C; Smith RC
Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
[TBL] [Abstract][Full Text] [Related]
2. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK).
Aguirre-Ghiso JA; Estrada Y; Liu D; Ossowski L
Cancer Res; 2003 Apr; 63(7):1684-95. PubMed ID: 12670923
[TBL] [Abstract][Full Text] [Related]
3. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system.
Lee DH; Yang Y; Lee SJ; Kim KY; Koo TH; Shin SM; Song KS; Lee YH; Kim YJ; Lee JJ; Choi I; Lee JH
Cancer Res; 2003 Aug; 63(15):4648-55. PubMed ID: 12907645
[TBL] [Abstract][Full Text] [Related]
4. Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer.
Taniguchi T; Kakkar AK; Tuddenham EG; Williamson RC; Lemoine NR
Cancer Res; 1998 Oct; 58(19):4461-7. PubMed ID: 9766679
[TBL] [Abstract][Full Text] [Related]
5. Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells in vitro.
Gallicchio MA; Kaun C; Wojta J; Binder B; Bach LA
J Cell Physiol; 2003 Oct; 197(1):131-8. PubMed ID: 12942549
[TBL] [Abstract][Full Text] [Related]
6. Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.
Foca C; Moses EK; Quinn MA; Rice GE
Gynecol Oncol; 2000 Nov; 79(2):244-50. PubMed ID: 11063652
[TBL] [Abstract][Full Text] [Related]
7. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro.
Stahl A; Mueller BM
Cancer Res; 1994 Jun; 54(11):3066-71. PubMed ID: 8187097
[TBL] [Abstract][Full Text] [Related]
8. Regulated localization confers multiple functions on the protease urokinase plasminogen activator.
Wells JM; Strickland S
J Cell Physiol; 1997 May; 171(2):217-25. PubMed ID: 9130470
[TBL] [Abstract][Full Text] [Related]
9. Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma.
Morii T; Yabe H; Morioka H; Yamada R; Nakagawa T; Toyama Y
Anticancer Res; 2000; 20(5A):3031-6. PubMed ID: 11062719
[TBL] [Abstract][Full Text] [Related]
10. The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion.
Albo D; Berger DH; Tuszynski GP
J Surg Res; 1998 Apr; 76(1):86-90. PubMed ID: 9695745
[TBL] [Abstract][Full Text] [Related]
11. Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells.
Ma Z; Webb DJ; Jo M; Gonias SL
J Cell Sci; 2001 Sep; 114(Pt 18):3387-96. PubMed ID: 11591826
[TBL] [Abstract][Full Text] [Related]
12. Expression and localization of the urokinase-type plasminogen activator receptor (uPAR) in the human placenta.
Nishida Y; Hayashi Y; Imai Y; Itoh H
Kobe J Med Sci; 1998 Feb; 44(1):31-43. PubMed ID: 9846056
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of epidermal growth factor-induced invasion by dexamethasone and AP-1 decoy in human squamous cell carcinoma cell lines.
Shiratsuchi T; Ishibashi H; Shirasuna K
J Cell Physiol; 2002 Dec; 193(3):340-8. PubMed ID: 12384986
[TBL] [Abstract][Full Text] [Related]
14. Aspirin inhibits highly invasive prostate cancer cells.
Lloyd FP; Slivova V; Valachovicova T; Sliva D
Int J Oncol; 2003 Nov; 23(5):1277-83. PubMed ID: 14532966
[TBL] [Abstract][Full Text] [Related]
15. Effects of N-(4-hydroxyphenyl) retinamide on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in prostate adenocarcinoma cell lines.
Tanabe T
Hiroshima J Med Sci; 2000 Mar; 49(1):67-72. PubMed ID: 10824459
[TBL] [Abstract][Full Text] [Related]
16. Involvement of the [uPAR:uPA:PAI-1:LRP] complex in human myogenic cell motility.
Chazaud B; Bonavaud S; Plonquet A; Pouchelet M; Gherardi RK; Barlovatz-Meimon G
Exp Cell Res; 2000 Aug; 258(2):237-44. PubMed ID: 10896774
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA.
Wang W; Abbruzzese JL; Evans DB; Chiao PJ
Oncogene; 1999 Aug; 18(32):4554-63. PubMed ID: 10467400
[TBL] [Abstract][Full Text] [Related]
18. Expression of urokinase-type plasminogen activator and its receptor is up-regulated during tendon healing.
Xia W; de Bock C; Murrell GA; Wang Y
J Orthop Res; 2003 Sep; 21(5):819-25. PubMed ID: 12919869
[TBL] [Abstract][Full Text] [Related]
19. Endostatin-induced modulation of plasminogen activation with concomitant loss of focal adhesions and actin stress fibers in cultured human endothelial cells.
Wickström SA; Veikkola T; Rehn M; Pihlajaniemi T; Alitalo K; Keski-Oja J
Cancer Res; 2001 Sep; 61(17):6511-6. PubMed ID: 11522648
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of uPA inhibits migration and PI3k/Akt signaling in glioblastoma cells.
Chandrasekar N; Mohanam S; Gujrati M; Olivero WC; Dinh DH; Rao JS
Oncogene; 2003 Jan; 22(3):392-400. PubMed ID: 12545160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
